Holtkamp N, Otteken A, Findhammer S, Miller V, Kurth R, Werner A
Paul-Ehrlich-Institut, Langen, Germany.
J Infect Dis. 2000 Feb;181(2):513-21. doi: 10.1086/315240.
Recently, combinations of antiretroviral drugs (highly active antiretroviral therapy [HAART]) have led to a dramatic reduction of human immunodeficiency virus type 1 (HIV-1)-related clinical symptoms. Success of treatment is defined as almost complete suppression of plasma viremia, although in a sizable fraction of patients this goal is not achieved. We characterized primary HIV-1 isolates from 2 cohorts of patients in which HAART failed in terms of viral suppression. One cohort showed clinical benefit and stable or increasing CD4+ T cell numbers despite high viral load. The second viremic cohort had no CD4+ T cell recovery and exhibited typical AIDS-related symptoms. Primary isolates from HAART patients with minor clinical symptoms used CXCR4 as the most relevant receptor on primary cells. Thus, for the first time, it is shown that patients improving clinically under HAART harbor relatively high viral loads with viruses preferring CXCR4 as coreceptor.
最近,抗逆转录病毒药物组合(高效抗逆转录病毒疗法[HAART])已使1型人类免疫缺陷病毒(HIV-1)相关临床症状大幅减少。治疗成功的定义为血浆病毒血症几乎完全受到抑制,不过相当一部分患者并未实现这一目标。我们对来自2组患者的原发性HIV-1分离株进行了特征分析,这2组患者在病毒抑制方面HAART治疗均告失败。其中一组患者尽管病毒载量很高,但仍显示出临床获益且CD4+T细胞数量稳定或增加。第二组病毒血症患者的CD4+T细胞未恢复,并表现出典型的艾滋病相关症状。来自临床症状较轻的HAART患者的原发性分离株在原代细胞上以CXCR4作为最相关的受体。因此,首次表明在HAART治疗下临床症状有所改善的患者体内携带着相对较高的病毒载量,其病毒更倾向于以CXCR4作为共受体。